A Phase 1 Study of Recombinant Anti-Epidermal Growth Factor Receptor (EGFR) Human-mouse Chimeric Monoclonal Antibody Injection in Patients With Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2018
At a glance
- Drugs CPGJ-602 (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sunshine Guojian Pharmaceutical
- 13 Sep 2018 Planned End Date changed from 31 Aug 2018 to 30 Nov 2018.
- 13 Sep 2018 Planned primary completion date changed from 30 Jun 2018 to 30 Oct 2018.
- 31 Aug 2018 Biomarkers information updated